{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Choriogonadotropin+Alpha",
    "query": {
      "intervention": "Choriogonadotropin Alpha"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T14:57:11.059Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01687712",
      "title": "Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infertility"
      ],
      "interventions": [
        {
          "name": "AFOLIA",
          "type": "DRUG"
        },
        {
          "name": "Gonal-f® RFF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fertility Biotech AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "42 Years",
        "sex": "FEMALE",
        "summary": "35 Years to 42 Years · Female only"
      },
      "enrollment_count": 1100,
      "start_date": "2013-11-25",
      "completion_date": "2016-11-14",
      "has_results": true,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-09-29T14:57:11.059Z",
      "location_count": 22,
      "location_summary": "Tempe, Arizona • Encino, California • Newark, Delaware + 18 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01687712"
    },
    {
      "nct_id": "NCT00006445",
      "title": "Down Syndrome - Comparison of Screening Methods in the 1st and 2nd Trimesters",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Down Syndrome",
        "Chromosome Abnormalities"
      ],
      "interventions": [
        {
          "name": "Ultrasound",
          "type": "PROCEDURE"
        },
        {
          "name": "Serum screen",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 45 Years · Female only"
      },
      "enrollment_count": 38000,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-02-22",
      "last_synced_at": "2026-09-29T14:57:11.059Z",
      "location_count": 10,
      "location_summary": "Denver, Colorado • Boston, Massachusetts • Royal Oak, Michigan + 6 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006445"
    },
    {
      "nct_id": "NCT02145247",
      "title": "Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [
        {
          "name": "hCG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "37 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 37 Years · Female only"
      },
      "enrollment_count": 39,
      "start_date": "2014-05",
      "completion_date": "2018-01",
      "has_results": true,
      "last_update_posted_date": "2019-08-12",
      "last_synced_at": "2026-09-29T14:57:11.059Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02145247"
    },
    {
      "nct_id": "NCT05450900",
      "title": "Can Biotin Supplementation be Used to Mask hCG Abuse?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Choriogonadotropin Alpha",
          "type": "DRUG"
        },
        {
          "name": "biotin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Microcellulose filler",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Sports Medicine Research and Testing Laboratory",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2022-10-27",
      "completion_date": "2023-02-02",
      "has_results": false,
      "last_update_posted_date": "2023-02-03",
      "last_synced_at": "2026-09-29T14:57:11.059Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05450900"
    },
    {
      "nct_id": "NCT06440850",
      "title": "Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Gland Follicular Carcinoma",
        "Thyroid Gland Oncocytic Carcinoma",
        "Thyroid Gland Papillary Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Diagnostic Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "I-131 Uptake Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Iodine I-131",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Recombinant Thyrotropin Alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ultrasound Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2024-07-15",
      "completion_date": "2026-11-22",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-09-29T14:57:11.059Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06440850"
    },
    {
      "nct_id": "NCT07557615",
      "title": "hCG Treatment for Rehabilitation From a TBI",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "Ovidrel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2026-10-01",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-09-29T14:57:11.059Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07557615"
    },
    {
      "nct_id": "NCT00505752",
      "title": "Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infertility"
      ],
      "interventions": [
        {
          "name": "AS900672-Enriched 50 microgram (mcg)",
          "type": "DRUG"
        },
        {
          "name": "AS900672-Enriched 100 mcg",
          "type": "DRUG"
        },
        {
          "name": "AS900672-Enriched 150 mcg",
          "type": "DRUG"
        },
        {
          "name": "Follitropin alfa 150 international unit (IU)",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human chorionic gonadotropin (r-hCG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "36 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 36 Years · Female only"
      },
      "enrollment_count": 520,
      "start_date": "2007-01",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-02-13",
      "last_synced_at": "2026-09-29T14:57:11.059Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00505752"
    },
    {
      "nct_id": "NCT00328926",
      "title": "Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypogonadotropic Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Luveris® 75 IU",
          "type": "DRUG"
        },
        {
          "name": "Luveris® 25 IU",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human follicle stimulating hormone (r-hFSH)",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human chorionic gonadotropin (r-hCG)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 11,
      "start_date": "2006-03",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2013-08-07",
      "last_synced_at": "2026-09-29T14:57:11.059Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00328926"
    },
    {
      "nct_id": "NCT02069808",
      "title": "Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Egg Donation"
      ],
      "interventions": [
        {
          "name": "Follistim",
          "type": "DRUG"
        },
        {
          "name": "Ganirelix",
          "type": "DRUG"
        },
        {
          "name": "Menotropins",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide",
          "type": "DRUG"
        },
        {
          "name": "Transvaginal ultrasound guided needle aspiration of oocytes",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Michigan Reproductive Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "28 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 28 Years · Female only"
      },
      "enrollment_count": 38,
      "start_date": "2014-04",
      "completion_date": "2017-03-08",
      "has_results": false,
      "last_update_posted_date": "2018-03-23",
      "last_synced_at": "2026-09-29T14:57:11.059Z",
      "location_count": 1,
      "location_summary": "Bloomfield Hills, Michigan",
      "locations": [
        {
          "city": "Bloomfield Hills",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02069808"
    },
    {
      "nct_id": "NCT03252223",
      "title": "Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome",
        "Healthy",
        "Anovulation",
        "Hyperandrogenism"
      ],
      "interventions": [
        {
          "name": "Recombinant Follicle Stimulating Hormone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "37 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 37 Years · Female only"
      },
      "enrollment_count": 33,
      "start_date": "2017-10-02",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-09-08",
      "last_synced_at": "2026-09-29T14:57:11.059Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03252223"
    }
  ]
}